Amid lay­off fears, As­traZeneca stakes a ‘For Sale’ sign on US cam­pus

Af­ter culling work­ers in Boston and Mary­land, As­traZeneca is con­sid­er­ing its op­tions for its US head­quar­ters cam­pus in Delaware. The lo­cal pa­pers have been re­port­ing that the phar­ma gi­ant has de­cid­ed to put its HQ up for sale, but is look­ing for a deal to lease it back.

Back in May the com­pa­ny trig­gered fears of a loom­ing re­struc­tur­ing that would like­ly trig­ger job cuts on the 30-acre site af­ter a spokesper­son con­firmed that it was con­sid­er­ing sell­ing the site and mov­ing to a new lo­ca­tion in the state.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER